

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 896
TO BE ANSWERED ON 14TH DECEMBER, 2018**

PRICE OF CARDIAC STENTS

896. SHRI RAJAN VICHARE:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether it is a fact that Government has revised the price of Dual Eluting Stents (DES) to Rs. 28000 and if so, the details thereof;
- (b) whether the revised price of the Stents is going to be a binding on the Private Hospitals which are still charging more than the prescribed prices on one or the other pretext and if so, the details thereof; and
- (c) the steps taken by the Government to ensure that the Dual Eluting Stents (DES) will be available to the patients in all the hospitals?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SHRI ASHWINI KUMAR CHOUBEY)**

(a): National Pharmaceutical Pricing Authority (NPPA) vide Gazette Notification No. S.O. 639(E) dated 12th February 2018 has notified the revised ceiling price of the Coronary Stents as follows:

- I. Bare Metal Stents: Rs. 7,660/-
- II. Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/Biodegradable Stents: Rs.27, 890/-

Subsequently, after considering the wholesale price index for the year 2017 over 2016, the prices of coronary stents have been revised with effect from 01.04.2018 as follows:

- I. Bare Metal Stents : Rs. 7,923/-
- II. Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents: Rs.28,849/-

(b): The ceiling price fixed by NPPA is applicable to all hospitals including private hospitals.

(c). NPPA under the Department of Pharmaceuticals is entrusted with the task of monitoring the availability of drugs, including notified medical devices, in the country, identifying shortages, if any, and taking remedial measures. Whenever, any complaint regarding non-availability of a particular medicine at a particular place is received, the concerned companies are asked by the NPPA to rush the supplies to that area.

No shortage of coronary stents in the country has been reported to NPPA after price regulation.